Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
Status:
Completed
Trial end date:
2016-05-24
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680
in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2
prior lines of therapy.